In March, GlaxoSmithKline(GSK) and the Texas A&M University System (TAMUS) announced the U.S. Department of Health and Human Services (DHHS) had approved the establishment of a $91 million (€70.3 million) influenza-vaccine manufacturing facility as the pillar [...]